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wrong study populations- an exemplar of
baseline vitamin D status of participants in
trials of vitamin D supplementation
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Abstract
Background: Research waste can occur when trials are conducted in the wrong populations. Vitamin D deficient
populations are most likely to benefit from vitamin D supplementation. We investigated waste attributable to
randomised controlled trials (RCTs) of supplementation in populations that were not vitamin D deficient.
Methods: In December 2015, we searched Pubmed, recent systematic reviews, and three trial registries for
RCTs of vitamin D with clinical endpoints in adults, and 25-hydroxvitamin D (25OHD) survey data relevant to
large (N ≥ 1000) RCTs. We investigated the proportion of RCTs that studied vitamin D deficient populations,
temporal trends in baseline 25OHD, and whether investigators in large RCTs considered relevant 25OHD survey data or
systematic reviews in their trial justifications.
Results: Of 137 RCTs of vitamin D with clinical endpoints, 118 (86%) reported baseline mean/median 25OHD, which
was < 25, 25–49, 50–74, and≥ 75 nmol/L in 12 (10%), 62 (53%), 36 (31%), and 8 (7%) RCTs, respectively. In 70% of RCTs,
baseline 25OHD was > 40 nmol/L. Baseline 25OHD increased over time. Before 2006, 38%, 62%, 0% and 0% of RCTs
had baseline 25OHD < 25, 25–49, 50–74, and≥ 75 nmol/L respectively; in 2011–15, the respective proportions were 9%,
49%, 37%, and 6%. Of 12 RCTs with baseline 25OHD < 25 nmol/L, 8 had neutral findings. Of 25 large RCTs (18 completed,
7 ongoing), 1 was undertaken in a vitamin D deficient population, 3 in vitamin D insufficient populations, and 17 had,
or probably will have, baseline 25OHD > 40 nmol/L. 44% (8/18) of large completed RCTs cited relevant prior population
25OHD data, and only 3/10 (30%) relevant prior systematic reviews.
Conclusions: Up to 70% of RCTs of vitamin D with clinical endpoints, 71% of large completed RCTs, and 100% of
ongoing large RCTs could be considered research waste because they studied cohorts that were not vitamin D
deficient.
Keywords: Vitamin D, Deficiency, Sufficiency, Randomized controlled trials, Research waste, Fracture, Cardiovascular
disease, Cancer, Mortality
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Background
Chalmers and Glasziou estimated that 85% of clinical re-
search is wasteful, with 50% of studies having design or
major methodological weaknesses [1]. In these compan-
ion reports, we assessed research waste in a single field -
calcium and vitamin D research. In the first report [2],
we focused on redundant research characterized by the
undertaking and publication of uninformative observa-
tional studies and randomised controlled trials (RCTs)
with surrogate endpoints long after the need for large
RCTs with ‘hard’ clinical endpoints was established. In
this second report, we address waste characterised by
conducting RCTs in poorly targeted population groups.
Clinical guidelines disagree on the serum 25-hydroxy-
vitamin D (25OHD) concentrations that constitute vita-
min D sufficiency. The Institute of Medicine
recommends ≥50 nmol/L to ensure adequate 25OHD
for 97.5% of the population, with a median target value
of 40 nmol/L [3], whereas the Endocrine Society recom-
mends ≥75 nmol/L [4]. However despite this disagree-
ment, there is general agreement that 25OHD <
25 nmol/L indicates deficiency, and recent UK guidance
on vitamin D supplementation is based on maintaining
25OHD above this threshold [5]. Mildly low 25OHD is
often termed vitamin D insufficiency, and moderately
low 25OHD vitamin D deficiency. Throughout the text,
we have used vitamin D deficiency to refer to 25OHD <
25 nmol/L, and insufficiency to 25OHD < 50 nmol/L [6].
Intuitively, supplementing populations that are vitamin
D deficient is more likely to produce benefits than sup-
plementing populations with higher 25OHD [7]. Poten-
tial benefits of vitamin D could be obscured if a high
proportion of participants in RCTs are vitamin D suffi-
cient. Thus, RCTs in cohorts that are vitamin D
sufficient are unlikely to show benefits of vitamin D supple-
mentation and could be considered research waste. Recent
systematic reviews of RCTs of vitamin D supplementation
have not shown benefits on skeletal or non-skeletal end-
points [8–11]. We set out to determine what proportion of
RCTs of vitamin D supplementation with clinical endpoints
has been conducted in vitamin D deficient populations, and
whether baseline 25OHD in such RCTs have changed over
time. We then focused on large RCTs either already com-
pleted or in progress, identified data on target population
vitamin D status available prior to the trial, and determined
whether the investigators reported relevant data on vitamin
D status. We also determined whether investigators re-
ported relevant systematic reviews in their trial justification,
as recommended [1, 12].
Methods
Literature searches
In December 2015, we searched Pubmed for RCTs of
vitamin D in adults (>18y) (Additional file 1: Table S1)
and for recent systematic reviews on clinical conditions and
major surrogate endpoints that were the primary endpoints
in identified RCTs (Additional file 1: Tables S2 and S3). We
included trials with an untreated or placebo group, trials
comparing different vitamin D doses, trials with or without
calcium supplements, and trials with multiple interventions
provided that 2 study arms differed only by the use of vita-
min D. We included quasi-randomized trials but excluded
trials where the method of allocation was sequential
or unreported, trials where vitamin D was adminis-
tered routinely post-thyroidectomy, and trials of hy-
droxylated vitamin D analogues. The flow of articles
is shown in Additional file 1: Figure S1.
In December 2015, we also searched ClinicalTrials.gov
(https://clinicaltrials.gov/), the International Standard
Randomised Controlled Trial Number (ISRCTN) regis-
try (http://www.isrctn.com/) and the Australian New
Zealand Clinical Trials Registry (ANZCTR) (http://
www.anzctr.org.au/) for completed and ongoing trials,
using vitamin D as the search term.
Finally, we obtained vitamin D status survey data from
published systematic reviews [13–17]. supplemented by
Medline, Embase, and Google searches using our vita-
min D search strategy and text words for the countries
of interest, and checked citations in reference lists.
Trial classification
We categorised each RCT according to whether clinical
or surrogate endpoints were reported in the Abstract (or
full-text where there was no Abstract), using the Insti-
tute of Medicine definition of surrogate outcomes as
“biomarker[s] intended to substitute for a clinical end-
point [and] expected to predict clinical benefit (or harm.
..) based on epidemiologic, therapeutic, pathophysio-
logic, or other scientific evidence” [18]. Where multiple
endpoints were reported, we recorded the most relevant
clinical endpoint, and if there were no clinical endpoints,
the most clinically relevant surrogate endpoint. Where
there were multiple publications from the same RCT, we
included the study with the most relevant clinical end-
point or the most clinically relevant surrogate endpoint.
Vitamin D status survey data
For large (N ≥ 1000) completed and ongoing RCTs, we
identified surveys of vitamin D status undertaken in the
same country and most similar population group, based
on age and sex, prior to the trial being undertaken. We
preferentially sought data from the five years before trial
inception or 10 years before trial completion/publication,
but used older data if we could not locate such data.
Analyses
A single author (MB or AA) extracted relevant data.
One author (MB) classified trials as having clinical or
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surrogate endpoints, and a second author (AG) checked
the classifications. We report the proportions of trials
with mean/median baseline 25OHD < 25, 25–49, 50–74,
≥75 nmol/L over time. In trials with mean/median base-
line 25OHD < 25 nmol/L and trials that reported a sub-
group analysis based on baseline 25OHD, two authors
(MB, AG) independently assessed whether the results of
the trial or subgroup analysis were beneficial, neutral, or
harmful and disagreements were resolved by consensus.
We examined primary trial publications, and trial pro-
tocols (where available), for large RCTs (N ≥ 1000) and
assessed whether trial investigators discussed prior rele-
vant evidence on vitamin D status of the intended trial
population in their justification for the trial. We also ex-
amined whether trial investigators discussed systematic
reviews of randomised trials relevant to the primary
endpoint that were available before trial recruitment
commenced in the Introduction section of the primary
publication.
Early 25OHD competitive binding protein (CBP) as-
says overestimated 25OHD concentrations [19]. As an
approximation, we used an adjustment factor of 0.54 for
CBP assays in papers published before 2000 [19]. and 0.76
to adjust for overestimation from the Nicholls’ immuno-
assay [20]. We have presented the RCT and survey data in
Tables 3 and 4 corrected for these overestimations.
Results
Baseline 25OHD in randomised controlled trials
From 4682 unique Pubmed records and 38 systematic
reviews, we identified 779 publications from 547 RCTs
of vitamin D, of which 137 (111,976 participants) re-
ported a clinical endpoint in the Abstract (Additional file
1: Tables S1, S2, S3 and Figure S1). Figure 1a shows that
the rate of publication of RCTs has increased markedly,
with 11 RCTs in 2001–5, 28 in 2006–10, and 88 in
2011–15. Mean/median baseline 25OHD was reported
in 118/137 (86%) RCTs (Fig. 1b), with 62%, 82%, and
93% of RCTs reporting baseline 25OHD before 2006, in
2006–10, and in 2011–15 respectively. Overall, mean/
median baseline 25OHD was < 25, 25–49, 50–74, and ≥
75 nmol/L in 12 (10%), 62 (53%), 36 (31%), and 8 (7%)
Fig. 1 Panel a shows the number of randomized controlled trials (RCTs) of vitamin D with clinical endpoints in the Abstract published over time
by year (bars) and cumulatively (line). Panel b shows the distribution of mean/median baseline 25-hydroxyvitamin D (25OHD) concentrations in
these RCTs. Panel c shows the 25OHD concentrations plotted against year of publication with a line of best fit. Panel d shows the proportion of
trials with mean/median baseline 25OHD < 25, 25–49, 50–74 and≥ 75 nmol/L by year of publication. Above each bar is the number of trials
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RCTs, respectively. In 70% of RCTs, baseline 25OHD
was > 40 nmol/L. Of 12 RCTs with baseline 25OHD <
25 nmol/L, 8 had neutral findings (Table 1).
Figure 1c and d show that mean/median baseline
25OHD has increased over time. Before 2006, 38% of
RCTs had 25OHD < 25 nmol/L, 62% between 25 and
49 nmol/L, and none ≥50 nmol/L. In 2006–10 and
2011–15, 0% and 9% respectively of RCTs had 25OHD
< 25 nmol/L, while 61% and 49% respectively had
25OHD 25–49 nmol/L, 26% and 37% respectively had
25OHD 50–74 nmol/L, and 13% and 6% respectively
had 25OHD ≥75 nmol/L.
Of 118 RCTs that reported mean/median baseline
25OHD, 19 (16%) reported a subgroup analysis for base-
line 25OHD (Table 2). The 25OHD thresholds used in
these analyses ranged from 20 to 80 nmol/L, with 5 ana-
lyses based on thresholds ≤25 nmol/L and 16 on thresh-
olds ≤50 nmol/L. Table 2 shows that 17 RCTs reported
similar results in the subgroup analysis and the main
analysis for the primary endpoint (16 both analyses neu-
tral, and 1 both analyses showed benefit for vitamin D).
Three of these 17 RCTs reported a benefit for vitamin D
for a secondary endpoint in a subgroup analysis. An-
other RCT did not report the result of the subgroup
analysis for the primary endpoint, but reported a benefit
for vitamin D for a secondary endpoint. Lastly, one RCT
had co-primary endpoints and neutral results in the
main analyses, but in the subgroup analyses there was a
benefit for vitamin D for one endpoint and neutral re-
sults for the other. Four of the five RCTs that reported
subgroup analyses with a 25OHD threshold of
≤25 nmol/L had neutral results for the primary endpoint
in the main analysis, and none of these 4 RCTs reported
beneficial effects for the primary endpoint in the sub-
group analysis.
Large randomised controlled trials and prior 25OHD
surveys
Tables 3 and 4 show 18 published RCTs of vitamin D
with ≥1000 participants (101,383 participants), and 7
planned and ongoing trials (79,939 intended partici-
pants). We included the pilot stage for the UK VIDAL
trial with 1600 participants, which aimed to continue
and recruit 20,000 participants, but has not yet received
funding for the full roll out. All trials were/are con-
ducted exclusively in North America, Europe, Australia
or New Zealand, except for two multinational trials with
countries from South America, Asia and Africa. 22/25
trials were in single countries: we did not examine prior
25OHD surveys for the 3 multinational trials.
Table 3 shows that only 8 [21–28] of the 18 completed
trials (44%) cited the vitamin D status of a population
similar to the recruited cohort in the primary publica-
tion. One further trial [29] discussed survey data in the
trial paper’s introduction, but this was not used in the
grant application. Investigators from two of these trials
[21, 22] had undertaken prior relevant 25OHD surveys.
Four of the eight trials cited old survey data, from at
least 16 years [24, 27] and 6–9 years [23, 26] before trial
recruitment. A trial from Finland that studied older
Table 1 Characteristics of 12 randomised controlled trials of vitamin D supplements in populations with mean/median 25OHD < 25 nmol/
L and clinical endpoints reported in abstract
Study Clinical endpoint Endpoint type Study Size (N) 25OHD Assay Mean/Median
25OHD (SD) (nmol/L)a
Result of Trialb
Brooke 1980 [44] Newborn outcomes Secondary 126 CBP 11 (1) Benefit
Chapuy 1994 [21] Fracture Primary 3270 CBP 20 (14) Benefit
Pfeifer 2000 [45] Risk of fall Secondary 148 Nicholls 19 (10) Neutral
Chapuy 2002 [46] Fracture Secondary 583 Incstar 22 (16) Neutral
Bischoff 2003 [47] Risk of fall Primary 122 Nicholls 23 (N/A) Neutral
Martineau 2011 [48] Tuberculosis sputum
culture conversion
Primary 126 LCMS/MS 21 (20) Neutral
Mosayebi 2011 [49] Multiple sclerosis
disability score
Primary 59 IDS 25 (7) Neutral
Amestejani 2012 [50] Atopic dermatitis Primary 60 Biosource 24 (5) Benefit
Schreuder 2012 [51] Pain Primary 84 Diasorin 20 (10) Neutral
Mozaffari-Khosravi 2013 [52] Depression score Primary 120 IDS 23 (N/A) Benefit
Hossain 2014 [53] Pregnancy outcomes Primary 200 Immunoassay 13 (N/A) Neutral
Bhan 2015 [54] All-cause mortality Secondary 105 LCMS/MS 22 (7) Neutral
aAdjusted for assay- see text for details
bBased on intention-to-treat analysis of all randomized participants for relevant endpoint. Assessed independently by two authors (MB, AG)
Studies are listed in Additional file 1: Table S3 and the Additional file 1: Reference list
Abbreviations: 25OHD 25-hydroxyvitamin D, SD standard deviation, N/A not available. CBP competitive binding protein; LCMS/MS- liquid chromatography
tandem mass-spectrometry
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adults (mean age 62y) cited survey data that lacked rele-
vance, being from the USA and from young Finnish
adults (mean age 38y) [30].
Table 4 shows that all four ongoing trials with access-
ible documents discuss the vitamin D status of their
intended trial population. One trial in Australia con-
ducted a pilot study that included assessment of vitamin
D status. The US VITAL trial which started recruitment
in 2010, used NHANES III (1988–94) data in its ration-
ale and design paper justification [31, 32].
Table 3 shows that baseline 25OHD in large com-
pleted RCTs and relevant survey 25OHD data were
comparable, apart from one Norwegian trial, where one
survey indicated considerably worse vitamin D status
than was observed in trial participants [23]. Only one
[21] of the completed trials was conducted in a popula-
tion that was clearly vitamin D deficient, based on trial
(mean baseline 25OHD 20 nmol/L) and survey data
(mean 11–23 nmol/L). Three trials [22, 24, 29] were
undertaken in populations comprised largely of partici-
pants with vitamin D insufficiency. Of the remaining 13
single country trials with baseline 25OHD or relevant
survey data, five trials [23, 27, 33–35] had mean baseline
25OHD ≥40 nmol/L and four trials 25OHD ≥50 nmol/L
[26, 28, 30, 36]. Four trials [25, 37–39] did not report
baseline 25OHD, but surveys and data from similar
RCTs suggest that baseline 25OHD in the RCT would
have been ≥40 nmol/L in three of these trials [25, 37,
38]. In these 13 trials, a substantial proportion of partici-
pants would have had 25OHD ≥50 nmol/L, consistent
with the IOM definition of vitamin D sufficiency [3].
Table 4 shows that, based on survey data from the
relevant population, all the ongoing single country trials
are likely to recruit participants in whom the mean/me-
dian baseline 25OHD will be > 40–50 nmol/L, and none
describe specific strategies for recruiting participants
with 25OHD < 25 nmol/L.
Large randomised controlled trials and citation of prior
systematic reviews of randomised controlled trials
We identified a relevant systematic review on vitamin D
and fracture [40] published prior to trial recruitment
starting for 8 completed large RCTs, and on mortality
[41] for 2 RCTs, but no prior systematic reviews on
colorectal adenoma or neonatal bone mineral content
for two RCTs (Table 3). Thus, systematic reviews capable
Table 2 Results of 18 randomised controlled trials of vitamin D supplements reporting subgroup analyses for baseline 25-
hydroxyvitamin D
Study 25OHD threshold (nmol/L) Subgroup Resulta Comparison to primary analysisa
Jackson 2006 [33] 32.2 Neutral Same
Jorde 2008 [55] 40 NR N/Ab
Wejse 2009 [56] 75 Neutral Same
Martineau 2011 [48] 20 Neutral Same
Rastelli 2011 [57] 50 Neutral Samec
Kjaergaard 2012 [58] 25 Neutral Same
Lehouck 2012 [59] 25 Neutral Sameb
Murdoch 2012 [60] 50 Neutral Same
Abou-Raya 2013 [61] 25 Benefit Same
McAlindon 2013 [62] 37.5 Neutral Same
Amrein 2014 [63] 30 Neutral Sameb
Lopez-Torres Hidalgo 2014 [64] 80 Neutral Same
Tran 2014 [65] 50 Neutral Same
Turner 2014 [66] 50 Neutral Same
Baron 2015 [36] 57.9 Neutral Same
Martineau 2015 [67] 50 Benefit Differentd
Miskulin 2015 [68] 37.5 Neutral Same
Sandoughi 2015 [69] 50 Neutral Same
Tukvadze 2015 [70] 25 Neutral Same
a Assessed independently by two authors (MB, AG)
b Benefit for secondary endpoint in subgroup analysis
c Primary endpoint not specified. Benefits in subgroup analyses for some but not all reported endpoints
d Two co-primary endpoints. Benefit in subgroup analysis for one co-primary endpoints. For other co-primary endpoint, subgroup analysis was neutral. In primary
analyses, results for both co-primary endpoints were neutral
Studies are listed in Additional file 1: Table S3 and Reference list
Abbreviations: 25OHD 25-hydroxyvitamin D, NR not reported; N/A not applicable
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of informing the trial justification and design were avail-
able before trial recruitment in 10/18 (56%) of com-
pleted large RCTs. Only three [28, 29, 42] of the 10
RCTs (30%) cited such a systematic review in their pri-
mary publication. Nine trials (50%) cited systematic re-
views that would have occurred after the decision had
been made to undertake the trial. Four of the seven
planned or ongoing trials with accessible relevant docu-
ments discuss systematic reviews in their protocols or
publications: for three of the trials, the systematic re-
views predate trial recruitment.
Discussion
Our results suggest a high proportion of research waste
in RCTs of vitamin D supplementation. The recent pro-
liferation of vitamin D RCTs was accompanied by in-
creasing baseline 25OHD concentrations and therefore a
declining proportion of RCTs conducted in vitamin D
deficient cohorts. Only 10% of trials were carried out in
populations that would be widely accepted as vitamin D
deficient, in which benefits of vitamin D supplementa-
tion still have not been unequivocally established (Table
1). Because many participants in recent trials were vita-
min D sufficient, they would be unlikely to benefit from
vitamin D. Further, their inclusion could have obscured
potential benefits from vitamin D for those participants
who were vitamin D deficient. This issue applies to
RCTs with mean/median baseline 25OHD in ranges
variously defined as sufficient (7% with 25OHD
≥75 nmol/L, 37% with 25OHD ≥50 nmol/L). It likely
also applies to the 33% of trials with baseline 25OHD
40–49 nmol/L in which a substantial proportion of par-
ticipants will have had 25OHD ≥50 nmol/L. Thus, 7–
37% of trials can be considered research waste, because
they were conducted in the wrong population, but this
proportion is as high as 70% if a 25OHD threshold for
sufficiency of 40 nmol/L was applied, based on the Insti-
tute of Medicine’s target median value.
Very importantly, research waste was prevalent in
large RCTs that were designed to inform clinical prac-
tice. Only 1 such trial was carried out in a vitamin D de-
ficient population and another 3 in populations with
vitamin D insufficiency. Twelve (71%) of the remaining
completed and 5 (100%) ongoing single country trials
had, or are likely to have, mean baseline 25OHD >
40 nmol/L, and based on survey and other trial data, we
estimate that about 50% would have 25OHD ≥50 nmol/
L. Failure to incorporate key available data during proto-
col development may have contributed to the high
prevalence of waste. Few (44%) of the large completed
RCTs cited or undertook prior relevant surveys of vita-
min D status in their intended trial population. Only
56% of large completed RCTs had a relevant systematic
review of randomised trials published prior to trial
recruitment starting and, of these, only 30% cited such a
review. When systematic reviews of randomised trials
were discussed, they tended to have been published after
the trial had commenced or been completed. Collect-
ively, this suggests that these large, costly RCTs were not
optimally designed to address the question of benefits of
vitamin D supplements.
An important strength of this study assessing research
waste is that we analysed the complete set of RCTs of
vitamin D published over 30 years. The results from this
single research area might not apply to other research
fields, and waste may be more prevalent in mature as
opposed to emerging areas of research. In assessing
whether trials cited 25OHD surveys or relevant system-
atic reviews, we examined primary publications and pro-
tocols where available. Our results may have changed if
we were able to examine grant applications and trial
protocols, but protocols were often not available, and we
had access to only one grant application [29]. Early
25OHD assays tended to overestimate 25OHD- we used
25OHD concentrations corrected for these overesti-
mates. The corrected values are approximations, but
nevertheless lower than the original values in the rele-
vant trials and surveys, and therefore the proportions of
participants with vitamin D deficiency in our analyses
are higher than in the original publications. Very few
RCTs reported the season when 25OHD measurements
were obtained. Although seasonal changes in 25OHD
will occur in all treatment arms, it is possible that sea-
sonal effects of 25OHD might confound some trial re-
sults. A limitation of this study is that the literature
search was conducted in December 2015.
The implications of this research are that the current
body of RCTs of vitamin D with clinical endpoints, in-
cluding large RCTs with ≥1000 participants, is largely
conducted in populations that are not vitamin D defi-
cient. Recent, large systematic reviews of these RCTs re-
port no benefits of vitamin D [8–11]. In trials included
in these meta-analyses reporting 25OHD, 72–75% had
baseline 25OHD < 50 nmol/L [10, 43], consistent with
Fig. 1d showing that the majority of trials prior to 2011
had baseline 25OHD < 50 nmol/L. Thus, it is reasonable
to conclude that current evidence is sufficient to exclude
benefits from vitamin D supplementation for unselected
community-dwelling individuals with 25OHD > 30–
40 nmol/L. Relatively few trials, including only 5003 par-
ticipants (Table 1), have been carried out in populations
with lower baseline 25OHD and their results are incon-
sistent, with only 33% of such trials reporting beneficial
results from vitamin D. Subgroup analyses of partici-
pants with lower 25OHD at baseline were frequently
undertaken but their results were invariably similar to
the results of the main analyses for the primary end-
point, even when the subgroup was restricted to people
Bolland et al. BMC Medical Research Methodology  (2018) 18:101 Page 11 of 14
with 25OHD ≤25 nmol/L. Therefore, it is uncertain
whether vitamin D supplementation benefits people with
clearly low 25OHD. Based on data from relevant 25OHD
surveys, the large RCTs currently underway will not test
the effects of vitamin D supplementation in deficient pop-
ulations and therefore are unlikely to address this know-
ledge gap. Instead of continuing to spend resources on
trials in vitamin D sufficient populations, investigators
should focus on vitamin D deficient populations. Food for-
tification policies [15, 16], together with independent
action by food manufacturers and new advice on supple-
mentation [5], make it even less likely that future trials in
deficient populations will be possible.
Our analyses suggest that up to 70% of RCTs with
clinical endpoints, 71% of large (N ≥ 1000) completed
RCTs, and 100% of ongoing large RCTs could be consid-
ered research waste because they studied cohorts with a
high proportion of vitamin D sufficiency. In our com-
panion paper [2], we reported that 69% of RCTs of vita-
min D conducted since 2005 with skeletal endpoints of
bone mineral density or fracture were research waste be-
cause they lacked novelty or did not add to existing clin-
ical knowledge. Taken together, these findings support
the very high proportions (> 85%) for research waste es-
timated by Chalmers and Glasziou [1].
Conclusions
We identified a very high proportion of research waste
in RCTs of vitamin D with clinical endpoints. Few RCTs
were carried out in vitamin D deficient populations most
likely to benefit from vitamin D supplementation, and
conversely most RCTs were carried out in populations
unlikely to benefit from supplementation. Few large
RCTs appeared to consider systematic reviews in their
design. Ongoing large RCTs share the same weaknesses
of previous trials. Strategies to improve the design of
RCTs should be introduced and studied to determine
whether they can reduce research waste.
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